关于他莫西芬及其与核受体相关的类型的研究进展
Ning Dong1, Yongli Du1, Yong Zheng1
1School of Chemistry & Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250353, China.
Future medicinal chemistry
|September 14, 2023
概括
塔莫西芬类似物通过调节雌激素受体 (ERs) 和ERRβ/γ来治疗乳腺癌,肝癌和骨质疏松症具有前景. 研究指导着开发基于他莫西芬的新型疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 内分泌学 在内分泌学.
背景情况:
- 塔莫西芬是乳腺癌,肝癌和骨质疏松症的关键药物.
- 它的三乙烯结构作为开发新型受体调节器的基础.
- 选择性雌激素受体调节剂 (SERM) 在治疗荷尔蒙依赖性疾病方面至关重要.
研究的目的:
- 总结一下对调节雌激素受体 (ERα),ERRβ和ERRγ) 的塔莫西芬类型的研究.
- 审查这些新型他莫西芬类型的结构-活性关系.
- 引导开发用于核受体介导疾病的新型他莫西芬类型药物.
主要方法:
- 关于他莫西芬类别的已发表研究的文献综述.
- 分析结构变化及其对受体调节的影响.
- 塔莫西芬类型活性与疾病治疗潜力的相关性.
主要成果:
- 已经合成了20多种新的他莫西芬类似物.
- 具体的类型表明ERα (16种化合物),ERRβ (1种逆激动剂) 和ERRγ (6种逆激动剂) 的强效调节.
- 这些受体调节器的已确立的结构-活性关系.
结论:
- 塔莫西芬类似物提供了除了乳腺癌之外的各种治疗潜力.
- 用他莫西芬衍生物向ERα,ERRβ和ERRγ是一个有前途的战略.
- 对这些类型的进一步研究可以为各种疾病提供新的治疗方法.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Signal Transduction: Overview
8.6K
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
8.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
The Nucleolus
8.9K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


